tetano
Editor, Senior Moderator
Am J Med Sci
. 2022 Feb 10;S0002-9629(22)00069-6.
doi: 10.1016/j.amjms.2022.01.022. Online ahead of print.
COVID-19 and the Cardiovascular System: An Update
Joshua K Salabei[SUP] 1 [/SUP], Zekarias T Asnake[SUP] 2 [/SUP], Zeeshan H Ismail[SUP] 2 [/SUP], Kipson Charles[SUP] 2 [/SUP], Gregory-Thomas Stanger[SUP] 2 [/SUP], Abdullahi H Abdullahi[SUP] 2 [/SUP], Andrew T Abraham[SUP] 2 [/SUP], Peters Okonoboh[SUP] 2 [/SUP]
Affiliations
Abstract
As COVID-19 continues to cause an increasing number of deaths worldwide, it is important that providers stay abreast with new research related to the pathophysiology of COVID-19 disease presentation states and clinical management. It is now well recognized that COVID-19 affects extrapulmonary organs, particularly the cardiovascular system. For example, cardiogenic shock has been increasingly observed in patients with COVID-19, owing to the various mechanisms involved and the affinity of the SARS-CoV-2 virus to cells comprising the cardiovascular system. In this review, we have briefly discussed the link between the cardiovascular system and COVID-19 infection, focusing on underlying mechanisms including but not limited to cytokine storm, direct virus-induced myocarditis, and ST-elevation myocardial infarction leading to cardiogenic shock. We have highlighted the cardiovascular risk factors associated with disease prognostication in COVID-19 patients. We have also briefly discussed vasopressors and inotropes used for treating shock and presented their mechanism of action, contraindications, and side effects in the hopes of providing a quick reference to help the provider optimize management of COVID-19 patients presenting with cardiovascular complications such as shock.
Keywords: COVID-19; SARS-CoV-2; cardiovascular complications; coronavirus; inotropes; myocarditis; shock; vaccine; vasopressor.
. 2022 Feb 10;S0002-9629(22)00069-6.
doi: 10.1016/j.amjms.2022.01.022. Online ahead of print.
COVID-19 and the Cardiovascular System: An Update
Joshua K Salabei[SUP] 1 [/SUP], Zekarias T Asnake[SUP] 2 [/SUP], Zeeshan H Ismail[SUP] 2 [/SUP], Kipson Charles[SUP] 2 [/SUP], Gregory-Thomas Stanger[SUP] 2 [/SUP], Abdullahi H Abdullahi[SUP] 2 [/SUP], Andrew T Abraham[SUP] 2 [/SUP], Peters Okonoboh[SUP] 2 [/SUP]
Affiliations
- PMID: 35151635
- DOI: 10.1016/j.amjms.2022.01.022
Abstract
As COVID-19 continues to cause an increasing number of deaths worldwide, it is important that providers stay abreast with new research related to the pathophysiology of COVID-19 disease presentation states and clinical management. It is now well recognized that COVID-19 affects extrapulmonary organs, particularly the cardiovascular system. For example, cardiogenic shock has been increasingly observed in patients with COVID-19, owing to the various mechanisms involved and the affinity of the SARS-CoV-2 virus to cells comprising the cardiovascular system. In this review, we have briefly discussed the link between the cardiovascular system and COVID-19 infection, focusing on underlying mechanisms including but not limited to cytokine storm, direct virus-induced myocarditis, and ST-elevation myocardial infarction leading to cardiogenic shock. We have highlighted the cardiovascular risk factors associated with disease prognostication in COVID-19 patients. We have also briefly discussed vasopressors and inotropes used for treating shock and presented their mechanism of action, contraindications, and side effects in the hopes of providing a quick reference to help the provider optimize management of COVID-19 patients presenting with cardiovascular complications such as shock.
Keywords: COVID-19; SARS-CoV-2; cardiovascular complications; coronavirus; inotropes; myocarditis; shock; vaccine; vasopressor.